vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and TRANSCONTINENTAL REALTY INVESTORS INC (TCI). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $12.1M, roughly 1.3× TRANSCONTINENTAL REALTY INVESTORS INC). TRANSCONTINENTAL REALTY INVESTORS INC runs the higher net margin — 68.8% vs -7.8%, a 76.5% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 2.3%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 0.7%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Transcontinental Realty Investors Inc. (TCI) is a U.S.-based real estate investment firm that owns, operates and develops a diversified portfolio of residential, commercial and mixed-use properties across core U.S. regional markets. It pursues long-term value growth via strategic property acquisitions, efficient asset management and tailored leasing solutions for individual and business tenants.
DERM vs TCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $12.1M |
| Net Profit | $-1.2M | $8.3M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | -28.9% |
| Net Margin | -7.8% | 68.8% |
| Revenue YoY | 27.3% | 2.3% |
| Net Profit YoY | -182.0% | 7577.8% |
| EPS (diluted) | $-0.04 | $0.97 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $12.1M | ||
| Q3 25 | $17.0M | $12.8M | ||
| Q2 25 | $15.0M | $12.2M | ||
| Q1 25 | $13.1M | $12.0M | ||
| Q4 24 | $12.6M | $11.8M | ||
| Q3 24 | $14.6M | $11.6M | ||
| Q2 24 | $14.9M | $11.8M | ||
| Q1 24 | $13.0M | $11.9M |
| Q4 25 | $-1.2M | $8.3M | ||
| Q3 25 | $-2.3M | $724.0K | ||
| Q2 25 | $-3.8M | $169.0K | ||
| Q1 25 | $-4.1M | $4.6M | ||
| Q4 24 | $1.5M | $108.0K | ||
| Q3 24 | $-2.4M | $1.7M | ||
| Q2 24 | $-3.4M | $1.5M | ||
| Q1 24 | $-10.4M | $2.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | -28.9% | ||
| Q3 25 | -9.0% | -10.9% | ||
| Q2 25 | -19.2% | -6.8% | ||
| Q1 25 | -25.3% | -5.3% | ||
| Q4 24 | 17.7% | -14.3% | ||
| Q3 24 | -19.8% | -14.4% | ||
| Q2 24 | -19.7% | -9.2% | ||
| Q1 24 | -77.4% | -11.2% |
| Q4 25 | -7.8% | 68.8% | ||
| Q3 25 | -13.6% | 5.6% | ||
| Q2 25 | -25.3% | 1.4% | ||
| Q1 25 | -31.0% | 38.5% | ||
| Q4 24 | 12.1% | 0.9% | ||
| Q3 24 | -16.3% | 14.7% | ||
| Q2 24 | -22.6% | 12.7% | ||
| Q1 24 | -80.1% | 21.4% |
| Q4 25 | $-0.04 | $0.97 | ||
| Q3 25 | $-0.09 | $0.08 | ||
| Q2 25 | $-0.16 | $0.02 | ||
| Q1 25 | $-0.18 | $0.53 | ||
| Q4 24 | $0.10 | $0.01 | ||
| Q3 24 | $-0.12 | $0.20 | ||
| Q2 24 | $-0.17 | $0.17 | ||
| Q1 24 | $-0.53 | $0.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $89.0M |
| Total DebtLower is stronger | $25.3M | $210.8M |
| Stockholders' EquityBook value | $31.9M | $846.7M |
| Total Assets | $94.6M | $1.1B |
| Debt / EquityLower = less leverage | 0.79× | 0.25× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $89.0M | ||
| Q3 25 | $24.9M | $82.7M | ||
| Q2 25 | $20.3M | $73.5M | ||
| Q1 25 | $21.1M | $88.6M | ||
| Q4 24 | $20.3M | $99.7M | ||
| Q3 24 | $22.5M | $131.6M | ||
| Q2 24 | $23.9M | $127.5M | ||
| Q1 24 | $24.1M | $130.8M |
| Q4 25 | $25.3M | $210.8M | ||
| Q3 25 | $25.2M | $223.5M | ||
| Q2 25 | $25.1M | $212.4M | ||
| Q1 25 | $25.0M | $198.2M | ||
| Q4 24 | $24.9M | $181.9M | ||
| Q3 24 | $19.8M | $180.3M | ||
| Q2 24 | $19.7M | $177.4M | ||
| Q1 24 | $14.7M | $178.3M |
| Q4 25 | $31.9M | $846.7M | ||
| Q3 25 | $25.9M | $838.4M | ||
| Q2 25 | $19.2M | $837.7M | ||
| Q1 25 | $21.5M | $837.3M | ||
| Q4 24 | $20.1M | $832.3M | ||
| Q3 24 | $10.9M | $832.2M | ||
| Q2 24 | $11.3M | $830.4M | ||
| Q1 24 | $13.0M | $828.9M |
| Q4 25 | $94.6M | $1.1B | ||
| Q3 25 | $85.2M | $1.1B | ||
| Q2 25 | $81.2M | $1.1B | ||
| Q1 25 | $85.0M | $1.1B | ||
| Q4 24 | $80.2M | $1.1B | ||
| Q3 24 | $64.0M | $1.1B | ||
| Q2 24 | $65.2M | $1.0B | ||
| Q1 24 | $66.6M | $1.0B |
| Q4 25 | 0.79× | 0.25× | ||
| Q3 25 | 0.97× | 0.27× | ||
| Q2 25 | 1.30× | 0.25× | ||
| Q1 25 | 1.16× | 0.24× | ||
| Q4 24 | 1.24× | 0.22× | ||
| Q3 24 | 1.81× | 0.22× | ||
| Q2 24 | 1.75× | 0.21× | ||
| Q1 24 | 1.13× | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-2.9M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.35× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-2.9M | ||
| Q3 25 | $-2.4M | $8.2M | ||
| Q2 25 | $-942.0K | $-2.9M | ||
| Q1 25 | $-2.8M | $-7.4M | ||
| Q4 24 | $2.2M | $1.3M | ||
| Q3 24 | $-1.2M | $13.7M | ||
| Q2 24 | $-5.2M | $-511.0K | ||
| Q1 24 | $-5.0M | $3.9M |
| Q4 25 | — | -0.35× | ||
| Q3 25 | — | 11.28× | ||
| Q2 25 | — | -17.24× | ||
| Q1 25 | — | -1.61× | ||
| Q4 24 | 1.46× | 12.13× | ||
| Q3 24 | — | 8.03× | ||
| Q2 24 | — | -0.34× | ||
| Q1 24 | — | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
TCI
Segment breakdown not available.
